Update on triplet therapy with ivosidenib, venetoclax, and azacitidine

During the 2022 ASCO Annual Meeting, the AML Hub spoke with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked...

Real-world prognostic significance of pretransplant NGS-MRD testing

The pre-MEASURE study is the largest dataset of NGS-MRD reported to date, in which the clinical use of NGS-MRD was validated using...

The impact of IDH2 mutant allele (R140/R172) on survival outcomes with enasidenib: An update from the IDHENTIFY trial

Mutations in the isocitrate dehydrogenase 2 (IDH2) gene occur in around 8–19% of...

ASCO22 Annual Meeting roundup – Ivosidenib

We summarize three poster presentations from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which covered safety data on Ivo +...

Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML

Lübbert et al. investigated the efficacy and safety of a 10-day decitabine regimen compared to...

Quizartinib, decitabine, and venetoclax combination therapy in patients with AML and prior exposure to FLT3 inhibitors

During the European Hematology Association (EHA) 2022 Congress, the triplet...

Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?

Ossenkoppele begins by introducing the study presented at the congress, outlining the study design...

The QuANTUM-First trial

During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR, about the initial findings from the QuANTUM-First...

Neutralizing antibody responses to SARS-CoV-2 in patients with AML or MDS

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) represents an increased risk for patients with immune dysfunction...

Should COVID-19 vaccination be postponed after AML therapy?

During the 63rd ASH Annual Meeting and Exposition, the AML hub spoke with Sabine Haggenburg, Amsterdam UMC, Amsterdam, NL. We asked, Should...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

Visual abstract | Eprenetapopt plus azacitidine as a post-allo-HCT treatment for patients with TP53-mutated AML and MDS: Results from a phase II trial

A representing key data from a phase II trial...

What is the clinical significance of secondary-AML-type mutations in de novo AML?

During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is...

TP53-mutated complex karyotype in patients with de novo or therapy-related MDS and AML

Identifying TP53-mutated complex karyotypes in myeloid neoplasms as a separate, highly aggressive entity will aid...

Molecular analysis of TP53-mutant AML and MDS-EB

The presence of TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts (MDS-EB) has been identified as a...